Inconsistencies among European Union pharmaceutical regulator safety communications: A cross-country comparison

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Zeitoun, Jean David ^a,b,c   Lefèvre, Jérémie H ^b,d   Downing, Nicholas ^e   Bergeron, Henri ^a,f   Ross, Joseph S ^g,h  

^a SCIENCES PO   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c Department of Proctology Deaconesses Hospital   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CNRS   (France)

^g Robert Wood Johnson Clinical Scholars Program   (United States)

^h YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FRANCE; HEALTH CARE POLICY; MEDICAL INFORMATION; MEDICAL SOCIETY; NETHERLANDS; PHARMACEUTICAL CARE; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PUBLIC HEALTH; SPAIN; UNITED KINGDOM; DRUG LEGISLATION; DRUG RECALL; EUROPEAN UNION; HUMAN; INTERNATIONAL COOPERATION; ORGANIZATION AND MANAGEMENT; STANDARDS;

DRUG;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CROSS-SECTIONAL STUDIES; EUROPEAN UNION; HUMANS; INTERNATIONAL AGENCIES; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; SAFETY-BASED DRUG WITHDRAWALS;

EID: 84908190355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109100     Document Type: Article

References (10)

1. Psaty BM, Goodman SN, Breckenridge A (2013) Advances in regulatory science at the Food and Drug Administration. JAMA 309: 2103-2104.
2. Psaty BM, Meslin EM, Breckenridge A (2012) A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA 307: 2491-2492.
3. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A (2008) Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 7: 818-826.
4. Carpenter D (2010) Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA: Princeton University Press.
5. Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, et al. (2012) Regulatory review of novel therapeutics-comparison of three regulatory agencies. N Engl J Med 366: 2284-2293.
6. Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, et al. (2010) A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf 33: 463-474.
7. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329: 15-19.
8. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, et al. (2008) Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300: 1887-1896.
9. Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37: 360-363.
10. Groves T, Godlee F (2013) The European Medicines Agency's plans for sharing data from clinical trials. BMJ 346: f2961.